Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Deloitte
Federal Trade Commission
AstraZeneca
Healthtrust
Novartis
US Army
Teva
Fish and Richardson
McKesson

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,765,001

« Back to Dashboard

Which drugs does patent 6,765,001 protect, and when does it expire?

Patent 6,765,001 protects VANOS and is included in one NDA.

This patent has eleven patent family members in nine countries.
Summary for Patent: 6,765,001
Title: Compositions and methods for enhancing corticosteroid delivery
Abstract:The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
Inventor(s): Gans; Eugene H. (Westport, CT), Wortzman; Mitchell S. (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:10/037,360
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 6,765,001

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medicis VANOS fluocinonide CREAM;TOPICAL 021758-001 Feb 11, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,765,001

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,217,422 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
7,794,738 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
8,232,264 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
7,220,424 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
7,771,733 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,765,001

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002360589 ➤ Sign Up
Brazil 0215254 ➤ Sign Up
Canada 2471041 ➤ Sign Up
China 1617730 ➤ Sign Up
European Patent Office 1465636 ➤ Sign Up
European Patent Office 2363150 ➤ Sign Up
Israel 162581 ➤ Sign Up
Japan 2005524614 ➤ Sign Up
Japan 2010280689 ➤ Sign Up
Mexico PA04006014 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Harvard Business School
Queensland Health
Baxter
Johnson and Johnson
McKinsey
Cantor Fitzgerald
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot